AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03687320 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
Study NCT04363580 — intervention group
Intervention type: OTHER
Intervention: Auditory processing disorder screening tool
Description: Screening tool : a questionnaire completed by the parents and the child's teacher and a mini-battery of tests composed of verbal and nonverbal assessments.~Questions for parents are grouped into four sections:~* Reference pattern and portrait of the child.~* Auditory history.~* History of speech and language development.~* School history.~The teacher questionnaire has seven sections:~* Portrait of the child.~* Reading and writing.~* Speaking.~* Mathematics.~* Music.~* Memory.~* Listening skills and understanding:~  * Concentration and organization.~ * Environment.~Mini-battery of tests:~* Dichotic Numeric Listening Test.~* Identification test of 15 patterns of frequency-varying sounds at each ear.~* Test of 10 monosyllables in noise per ear.~* Auditory memory test by measuring the range of figures (instead of words in order to reduce the contribution of language processing).
Study NCT02037594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Information (Active Control)
Description: Standard of Care Information about PrEP
Study NCT00585910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine and OROS Methylphenidate
Description: Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
Study NCT00452244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Simvastatin 40mg/QD po daily every 3 weeks
Study NCT00452244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib only
Description: gefitinib 250mg/QD po daily every 3 weeks
Study NCT00452244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib only
Description: gefitinib 250mg/QD po daily every 3 weeks
Study NCT01163201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg cells
Description: Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10\^6/kg, 10 x 10\^6/kg, 30 x 10\^6/kg, 100 x 10\^6/kg and 300 x 10\^6/kg)
Study NCT01163201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3+ Teff cells
Description: Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10\^6 cells/kg, 6 x 10\^6 cells/kg, 9 x 10\^6 cells/kg, 12 x 10\^6 cells/kg, and 15 x 10\^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
Study NCT01163201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously on Days -8 through -6, 25 mg/m\^2 over 1 hour
Study NCT01163201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously on Day -7 and -6, 60 mg/kg
Study NCT01163201 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Given on Days -4 through -2, 165 cGY twice a day.
Study NCT01163201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation
Description: Infusion given on day 0
Study NCT04133012 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Samplings
Description: * blood samples~* rectal biopsies~* nodes biopsies~* cutaneous fat tissues biopsies~* semen sample
Study NCT04688645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution
Description: Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
Study NCT04688645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
Study NCT03707626 — intervention group
Intervention type: OTHER
Intervention: Wellens Sign
Description: presence or absence in presence of coronary collaterals to LAD
Study NCT03926299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FotonaSmooth SP® Spectro laser device
Description: dual laser treatment with thermal Nd:YAG and ablative Er:YAG (Fotona medical device), 4 laser sessions 4-8 weeks apart.
Study NCT03926299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment
Description: 6 months standard treatment with topical steroid cream (high dose for the first two months, medium dose for the next two months, low dose for the last two months)
Study NCT02033668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776 for SQ administration
Description: Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
Study NCT02033668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776 for IM administration
Description: Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
Study NCT02033668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK933776 for IV administration
Description: Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
Study NCT00676663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Entinostat 5 mg tablet orally once per week
Study NCT05047861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket shield technique with autogenous dentin graft
Description: The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth
Study NCT05047861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket shield technique with alloplast graft
Description: The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft
Study NCT03133247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: PD-L1
Study NCT03348839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeLLY service
Description: Telesurveillance and therapeutic support
Study NCT00676663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Exemestane 25 mg tablet orally once daily
Study NCT00676663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exemestane
Description: Exemestane 25 mg tablet orally once daily
Study NCT02037594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Adherence Support (Active Control)
Description: Standard of care information and instruction about PrEP adherence.
Study NCT02743182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Study NCT02254629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Clostridium Butyricum
Description: probiotic:2 tablets/ times, 3 times / day for 2 weeks
Study NCT02254629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Clostridium Butyricum
Description: probiotic:2 tablets/ times, 3 times / day for 2 weeks
Study NCT02480556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual seperation of the placenta
Description: manual separation of the placenta will be done immediately after fetal extraction \& cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
Study NCT02480556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative separation of placenta
Description: Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu \& uterus is massaged awaiting spontaneous placental separation
Study NCT00253578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT00253578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03152370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7046
Description: oral administration
Study NCT01002651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat bran extract
Description: soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
Study NCT01002651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
Study NCT00825188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone, amlodipine
Description: Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
Study NCT00825188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: Eplerenone 25-50mg daily x 8 weeks
Study NCT00825188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: eplerenone 25- 50 mg daily for 8 weeks
Study NCT00825188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5-10mg daily for 8 weeks
Study NCT02379169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil & lutein
Description: Standardised sea buckthorn seed and pulp oil complemented with lutein
Study NCT02379169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Triglycerides of medium chain fatty acids
Study NCT03818750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not.~Subjects will be exposed to 288 ads set up.
Study NCT03818750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test
Description: Questionnaire
Study NCT00890747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT00890747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00890747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02346461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ManNAc
Description: At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.
Study NCT02346461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ManNAc
Description: At doses of 6 g twice daily (12 g per day).
Study NCT03940729 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chlorhexidine Topical
Description: In the Malmö needle exchange program, people who inject drugs (PWID) are repeatedly screened for S aureus colonization during one year. Those colonized will repeatedly shower with chlorhexidine during the following year. The infection frequency will be compared between the two periods.
Study NCT02311114 — intervention group
Intervention type: OTHER
Intervention: In Depth interview
Description: In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
Study NCT02311114 — intervention group
Intervention type: OTHER
Intervention: Observational fieldwork
Description: Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
Study NCT02311114 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Surveys with participants will be conducted using validated survey tools.
Study NCT00014079 — intervention group
Intervention type: GENETIC
Intervention: DNA stability analysis
Study NCT00014079 — intervention group
Intervention type: GENETIC
Intervention: loss of heterozygosity analysis
Study NCT00014079 — intervention group
Intervention type: GENETIC
Intervention: microsatellite instability analysis
Study NCT02254629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laxative Polyethylene Glycol
Description: laxative：2000 ml.
Study NCT02254629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laxative Polyethylene Glycol
Description: laxative：2000 ml.
Study NCT01016600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT01412411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritionl Education
Description: to assess the change in behaviour
Study NCT01412411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron Supplementation along with Nturition Eductaion
Study NCT01412411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple micronutrient fortification plus Nutrition Education
Study NCT01398540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IXIARO
Description: 2 immunizations (0,5ml) with a 28 day interval
Study NCT03152370 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long Course Chemoradiotherapy (LCRT)
Description: pelvic radiotherapy
Study NCT03152370 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Radiotherapy (SCRT)
Description: pelvic radiotherapy
Study NCT03152370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: chemotherapy
Study NCT03152370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid/5-FU/oxaliplatin (mFOLFOX-6)
Description: chemotherapy
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: See arm/group descriptions
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: See arm/group descriptions
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: See arm/group descriptions
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Diphosphate
Description: See arm/group descriptions
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Monophosphate
Description: See arm/group descriptions
Study NCT01465594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral catheter after EERPE/ RALP
Description: transurethral catheter after EERPE/ RALP
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uridine Triphosphate
Description: See arm/group descriptions
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: See arm/group descriptions
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B 6
Description: See arm/group descriptions
Study NCT03738943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxal 5'-Phosphate
Description: See arm/group descriptions
Study NCT01465594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic catheter after EERPE /RALP
Description: suprapubic catheter after EERPE /RALP
Study NCT00585468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Myfortic 720 mg orally twice daily
Study NCT04107480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic trans-sphenoidal adenoma resection
Description: Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice.
Study NCT01285180 — intervention group
Intervention type: DRUG
Intervention: Daxas
Description: 500 microgram, oral, once daily as add-on therapy to existing therapy
Study NCT01205139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 7 days
Study NCT04107480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine Agonists
Description: The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care.
Study NCT03884621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHP Group
Description: The Enhanced post-discharge home-based care program (EHP) plus usual care
Study NCT01205139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablet once daily for 7 days
Study NCT01205139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + TDF
Description: 150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
Study NCT01205139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + TMC278
Description: 150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
Study NCT01205139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25 mg tablet once daily for 11 days
Study NCT01205139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 11 days
Study NCT01441622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL539 (SRETT)
Description: recording data with AL539 (SRETT)
Study NCT00957840 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: NIRS, aEEG, and CSF concentration of biomarkers
Description: NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
Study NCT01557400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Oral powder for suspension